Need professional-grade analysis? Visit stockanalysis.com
$2.11B
N/A
N/A
N/A
Galapagos NV ADR (GLPG) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $28.91, down 1.26% from the previous close.
Over the past year, GLPG has traded between a low of $25.07 and a high of $37.62. The stock has gained 13.4% over this period. It is currently 23.2% below its 52-week high.
Galapagos NV ADR has a market capitalization of $2.11B.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Side-by-side comparison against top Healthcare peers.